Literature DB >> 11752111

Relationship between rate and extent of G protein activation: comparison between full and partial opioid agonists.

John R Traynor1, Mary J Clark, Ann E Remmers.   

Abstract

Opioid agonists acting at their receptors alter intracellular events by initiating activation of various types of Gi/Go proteins. This can be measured by the binding of the stable GTP analog [(35)S]guanosine-5'-O-(3-thio)triphosphate ([(35)S]GTPgammaS). In this study agonist efficacy is defined by the degree to which an opioid stimulates the binding of [(35)S]GTPgammaS. This allows for a definition of full and partial agonists; a full agonist causing a greater stimulation of [(35)S]GTPgammaS binding than a partial agonist. The hypothesis that the rate of agonist-stimulated [(35)S]GTPgammaS binding is dependent upon agonist efficacy was tested using membranes from C6 glioma cells expressing mu- or delta-opioid receptors. At maximal concentrations the rate of agonist-stimulated [(35)S]GTPgammaS binding followed the efficacy of mu-agonists in stimulating [(35)S]GTPgammaS binding, i.e., [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin > morphine > meperidine > butorphanol > nalbuphine. At submaximal concentrations of mu- or delta-full agonists the [(35)S]GTPgammaS association rate was also reduced, such that the rate of [(35)S]GTPgammaS binding correlated with the extent of [(35)S]GTPgammaS bound, whether this binding was stimulated by a full agonist or a partial agonist. Agonists also stimulated [(35)S]GTPgammaS dissociation, showing that binding of this stable nucleotide was reversible. Comparison of the delta-agonists [D-Ser(2),Leu(5)]-enkephalin-Thr and (+/-)-4-((alpha-R*)-alpha-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxylbenzyl)-N,N-diethylbenzamide, a compound with slow dissociation kinetics, showed the measured rate of G protein activation was not influenced by the agonist switching between receptors. The results are consistent with the idea that the active state(s) of the receptor induced by full or partial agonists is the same, but the number of activated receptors determines the rate of G protein activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752111     DOI: 10.1124/jpet.300.1.157

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Differential activation of G-proteins by mu-opioid receptor agonists.

Authors:  Zuzana Saidak; Katherine Blake-Palmer; Debbie L Hay; John K Northup; Michelle Glass
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

2.  Mechanisms of G protein activation via the D2 dopamine receptor: evidence for persistent receptor/G protein interaction after agonist stimulation.

Authors:  K Quirk; D J Roberts; P G Strange
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

3.  Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists.

Authors:  Elizabeth M Rosethorne; Robert J Turner; Robin A Fairhurst; Steven J Charlton
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-08       Impact factor: 3.000

4.  Collision coupling, crosstalk, and compartmentalization in G-protein coupled receptor systems: can a single model explain disparate results?

Authors:  Christopher J Brinkerhoff; John R Traynor; Jennifer J Linderman
Journal:  J Theor Biol       Date:  2008-08-08       Impact factor: 2.691

5.  The role of amygdalar mu-opioid receptors in anxiety-related responses in two rat models.

Authors:  Marlene A Wilson; Lorain Junor
Journal:  Neuropsychopharmacology       Date:  2008-01-23       Impact factor: 7.853

6.  Alpha 2A-adrenoceptor-specific stimulation of [35S]GTP gamma S binding to membrane preparations of rat frontal cortex.

Authors:  Oliver Pulges; Ago Rinken
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.